Post by PressRelease on Mar 21, 2024 7:30am
New Press Release - Knight Therapeutics Reports Fourth Quarter and Year-End 2023 Results
Comment by
luscar99 on Mar 21, 2024 10:42am
Ugly Q4. Lower revenues, higher expenses, weakening balance sheet. Everything was bad. Ironically, the only "good news" was that their loss in Argentina was smaller when reported in $CAD due to the cratering of thevArgetinian currency vs $CAD. Management should be ashamed.
Comment by
luscar99 on Mar 21, 2024 11:47am
Yes. Q4 was ugly. That's why idiots refer to the annual results.
Comment by
longrun86 on Mar 21, 2024 5:58pm
Q4 was gross and the 2024 Guidance was underwhelming. The impairment bothers me a bit but I also understand that currency issue. I haven't listened to the conference call recording but will this weekend. Overall I am dissapointed but will hang tight for now. LR